ALKEM stock
ALKEM is in a mixed news setup around Pharmaceuticals; 2 recent stories are active but the saved quote move at +0.99% keeps the read balanced.
ALKEM has built a mixed coverage cluster in the last 27 days. The strongest recurring theme is Pharmaceuticals, while the current weighted impact score is +2 from 1 bullish, 1 bearish, and 0 neutral stories across 2 sources.
ALKEM is last saved at ₹5,664 with a day move of +0.99%. That quote should be read with the article tape: a positive headline only matters if price, volume, and follow-through confirm it; a negative headline matters more when it keeps repeating across multiple publishers.
This is ALKEM's latest financial report. We don't have past reports to compare, but the company recorded a profit of Rs 676.23 crore from sales of Rs 2286.83 crore. This information helps you understand how much money the company made and kept in this period. This hub keeps the permanent stock view separate from short-lived article pages, so search engines and users get one accumulated view instead of scattered programmatic summaries.
Economic Times · 11 days ago · 2 min read
Mint · 8 Jun 2026 · 2 min read
Economic Times · 3 Jun 2026 · 2 min read
Economic Times · 2 Jun 2026 · 2 min read
Economic Times · 2 Jun 2026 · 2 min read
How ALKEM stacks against related names in this news cluster
ALKEM has appeared across 2 recent stories from 2 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.
ALKEM coverage is currently mixed, with 1 bullish, 1 bearish, and 0 neutral analyzed stories in the recent window.
Recent ALKEM coverage is clustering around Pharmaceuticals and Healthcare. Related names showing up alongside ALKEM include DRL, SUNPHARMA, JBCCHEM.
Use this page as a coverage hub for ALKEM: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.
2 recent mentions linked to ALKEM
TopicHealthcare1 recent mentions linked to ALKEM
StockDRLRelated news cluster with 2 links
Latest storyBearish Risk: Indian Pharma Faces Regulatory Heat After Spurious DrugThe Indian pharma sector has seen bumper returns recently, but this incident introduces significant
How retail crowds and channels are talking about ALKEM right now — context for your own research, not a trade call.